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TABLE 1. Subject characteristics 
ANTI-INFLAMMATORY EFFECT OF KETOTIFEN, DSCG. AND BDP 943 
Ketotifen (n= 13) DSCG (n=9) BDP (n= 10) 
Age (years) 
Sex (M:F) 
Symptom score 
~ PEF (1 min ‘) 
FEV,% pred. 
D,,, 0-W 
~ IgE (IU ml ‘) 
27 (1650) 26 (20-31) 30 (2344) 
716 6:3 713 
3.5 (1.5-10.5) 3.7 (1.0-6.4) 5.0 (l.lL128) 
450 (320-580) 350 (300-540) 425 (250-550) 
72.0 (58.7X39.9) 63.2 (57.6-90.5) 66.0 (59.4-74.9) 
0.32 (0.1 l-2.24) 0.34 (0.15-2.56) 0.68 (0.21-2.03) 
1045.0 (276-3430) 500.0 (243-925) 749.9 (171-1953) 
PEF, peak expiratory flow; Dlninr dose of methacholine as a measure of bronchial sensitivity. 
Unit: equal to 1 min of 1.0 mg ml ~ ’ aerosol inhalation of methacholine. 
and in patients with asthma it can inhibit the release of 
histamine and leukotrienes from basophils (7). Clinical 
studies done in Europe have shown that prophylactic 
treatment with ketotifen can be effective in patients with 
asthma (89). Clinical studies have shown ketotifen is 
effective in treatment of asthma when compared with 
placebo (lo), theophylline (1 l), and DSCG (12); and 
ketotifen is shown to have dose-reducing effects on 
steroids (13,14). Though anti-inflammatory effects of 
inhaled corticosteroids have already been proven (15-17) 
these effects have not been examined for ketotifen and 
DSCG. 
This study was therefore undertaken to compare the 
effects of ketotifen, DSCG, and beclomethasone dipropion- 
ate (BDP) on bronchial mucosa, asthma symptoms, and 
bronchial responsiveness, in patients with asthma. 
Methods 
SUBJECTS 
Thirty-two asthmatic patients were recruited from our 
hospital. Asthma was diagnosed based on the clinical 
history of intermittent chest tightness, wheezing, coughing, 
or shortness of breath and documented reversible airflow 
obstruction [20% improvement in peak expiratory flow 
(PEF) or forced expiratory volume in 1 s (FEV,), either 
spontaneously or in response to inhaled &-agonists]. All 
patients had mild to moderate atopic asthma, which was 
diagnosed according to two or more positive skin prick test 
results and the presence of aeroallergen-specific IgE. No 
patients had received inhaled or oral corticosteroids, 
or any other anti-inflammatory drugs such as sodium 
cromoglycate, or nedocromil sodium, in the preceding 
4 months. The patients used &agonists only when 
necessary. Patients who smoked or whose FEV, was less 
than 50% of the predicted value were excluded. Patients 
showed no signs of upper or lower respiratory disease for 
at least 2 weeks before entering the study. The Ethics 
Committee of Toho University School of Medicine 
approved the study protocol, and all subjects gave informed 
written consent. 
STUDY DESIGN 
At the initial visit, the patients were examined and a full 
disease history was obtained. Skin prick tests to common 
aeroallergens (house-dust mite, cat fur, dog fur and grass 
pollen) were performed and blood was taken for total 
and specific IgE (Phadebas RAST; Pharmacia, Uppsala, 
Sweden). The patients measured their PEF in the morning 
and evening using a personal best peak flowmeter (Health 
Scan, Cedar Grove, NJ, U.S.A.), and recorded their results 
on a diary card. After 6 days, patients were readmitted after 
having abstained from inhaled &agonists for at least 12 h. 
Spirometry was performed and methacholine inhalation 
test measurements were taken according to the method of 
Takishima et al. (18). Briefly, using an ‘Astograph’ (TCK- 
6OOOCV, Chest MI Co., Tokyo, Japan), the dose-response 
curves of respiratory resistance were determined. Baseline 
values were measured after the inhalation of an isotonic 
saline solution, after which increasing concentrations of 
methacholine hydrochloride in isotonic saline were inhaled, 
starting at a concentration of 49 pg ml - ’ and increasing 
stepwise to 25 000 pg ml ~ I. The cumulative dose at the 
level the reciprocal of the respiratory resistance started to 
decrease linearly, was determined as the minimum level 
showing bronchial sensitivity (D,,,). After 6 days, the 
patients were readmitted to the hospital, and fibreoptic 
bronchoscopy and bronchial biopsy were performed. Eight 
symptoms, i.e. nocturnal wheezing; nocturnal coughing; 
morning chest tightness; wheezing during the day; limita- 
tion of activity; and the effect of exercise, cold air, and dust 
on asthma symptoms; were evaluated daily using a 4-grade 
system (3: severe, 2: moderate, 1: mild, 0: none), and the 
sum of the eight scores was expressed as the ‘symptom 
score’ of the day. Symptom score and PEF for the initial 
2 weeks were averaged to obtain the initial symptom score 
and the initial PEF. After-treatment symptom score and 
PEF were calculated from the records during the final 
2 weeks of treatment. 
This study is composed of a randomized parallel design 
without placebo, in which ketotifen, DSCG and BDP 
preparations were arranged at random and numbered by a 
third person (pharmacist) in our hospital. Prescriptions 
were then written out as the order by the doctor (M.H.). In 
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FIG. 1. Mean symptom score in each treatment group. 
Within-group comparisons were performed with Student’s 
t-test (**P<O.Ol). Comparisons of each treatment effects 
(before-treatment value minus after-treatment value) were 
analysed by the Bonferroni test (*P<O.O5). 
this way, the patients were randomly allocated to one of the 
following treatment groups, i.e. oral ketotifen (Sandoz Ltd., 
Basle, Switzerland) at a dose of 1 mg twice daily, 2 mg q.i.d. 
DSCG for inhalation (Fujisawa Pharmaceutical Co., 
Tokyo, Japan), or 1OOpg q.i.d. BDP for inhalation 
(Schering-Plough Pharmaceutical Co., Kenilworth, NJ, 
U.S.A.), for 3 months. Ketotifen, given in a dose of 2 mg 
daily for adults and in a dose of l-2 mg for children, is 
reported to result in a significant improvement of asthma 
symptoms (19). The dose of DSCG (8 mg day - ‘) is equally 
effective to the inhaled BDP (4OOpg day - ‘) (R. Beasley, 
pers. comm.). The patients recorded daily use of oral 
ketotifen, or DSCG or BDP inhalation in their patient 
diary. Blood test, pulmonary function test, and bronchial 
responsiveness were conducted in week 11 during treat- 
ment, and bronchoscopy and biopsy were conducted during 
week 12. No patients experienced deterioration of asthma 
symptoms during the treatment period. 
FIBREOPTIC BRONCHOSCOPY IMMUNOHISTOCHEMISTRY 
On the day of the bronchoscopy, subjects fasted from Frozen sections (4pm thick) of the bronchial biopsy speci- 
9 a.m. Before the examination, each patient received an mens were cut on a cryostat, placed on albumin-coated 
i.m. injection of 0.5 mg atropine sulphate and 15 mg pen- slides, air-dried for 30 min, and fixed for 15 min in cold 
tazocine (Yamanouchi Pharmaceutical Co., Tokyo, Japan). acetone ( - 20°C). Sections were treated with 0.3% H,O, in 
After the throat was anaesthetized with a 4% lidocaine methanol for 10 min to block endogenous peroxidase, then 
spray, all patients inhaled 200 lug of salbutamol in order to for another 30 min with 10% normal porcine serum to 
prevent bronchoconstriction. A bronchoscope (BF type 20, suppress non-specific absorption of immunoglobulins, and 
Olympus Co., Tokyo, Japan) was inserted through the incubated for 24 h at 4°C with the following primary 
mouth, and the pharynx, trachea and bronchi were anaes- monoclonal antibodies to identify these cell types: eosino- 
thetized with 2% lidocaine. Oxygen at 4 1 mini i was phils [EG2: cleaved form of eosinophil cationic protein 
administered via nasal cannulae throughout the procedure. (ECP), dilution 1:30; Kabi Pharmacia Diagnostics, 
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FIG. 2. Mean peak expiratory flow (PEF) in each treat- 
ment group. Within-group comparisons were performed 
with Student’s t-test (**P<O.Ol). Comparisons of each 
treatment effects (before-treatment value minus after- 
treatment value) were analysed by the Bonferroni test 
(*P<o.o5, **P<o.ol). 
Biopsy forceps (FB-15C, Olympus) were used to collect two 
or three specimens from the segmental divisions of the right 
main bronchi. The specimens for immunohistochemistry 
were mounted in ornithine carbamyl transferase compound 
(Miles Scientific Naperville, IL, U.S.A.), frozen rapidly in 
dry ice-acetone, and kept at - 70°C until 2 months before 
sectioning. After bronchoscopy, inhalation of 200 pg sal- 
butamol was administered. In order to assess the degree of 
the inflammatory cell infiltration into the airways, second 
biopsy specimens were taken from the same airway sites 
despite the possibility that they might include scarred or 
healed tissue. All patients tolerated the procedure well, and 
no patients experienced bronchoconstriction. 
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Uppsala, Sweden, No. lo-9196-011, mast cells (AAl: tryp- 
tase, dilution 1:50; Dako, Glostrup, Denmark, No. 
M7052), CD3 (mature T cells: Beckton Dickinson, San 
Jose, CA, U.S.A. No. 7340) CD4 (helper/inducer T cells: 
Beckton Dickinson, San Jose, CA, U.S.A. No. 6320) and 
CDS (suppressor/cytotoxic T cells: dilution 1:30 each; 
Beckton Dickinson, San Jose, CA, U.S.A. No. 6310). After 
being washed with phosphate-buffered saline (PBS), the 
sections were reacted with peroxidase-labelled anti- 
mouse immunogloblin G (IgG) (Biosource International, 
Camarillo, CA, U.S.A.) as the secondary antibody, for 
60 min at room temperature, and then washed again with 
PBS The peroxidase reaction was developed in 3.3- 
diaminobenzidine solution (20 mg dl ’ in Tris buffer, 
pH 7.6) containing 0.03% H,O,. Finally, the nuclei were 
counterstained with methylene green and, after being 
washed in running water, dried with alcohol and treated 
with xylol. Negative controls were performed by omission 
of the primary antibodies and by using mouse IgG, 
myeloma proteins as a substitute for the primary antisera. 
QUANTIFICATION 
To avoid the observer bias, the specimens were all 
coded prior to analysis by a co-author (J.J.S.) and the 
blinded slides were examined (by Y.N.) microscopically 
(Olympus) at x 400 magnification. Numbers of positively 
stained cells were counted in the lamina propria, beneath 
the epithelial basement membrane, in an area excluding 
mucosal glands, bronchial smooth muscle and vessels. 
An interactive video display system (Olympus) and 
software for two-dimensional image analysis (NEC Co., 
Tokyo, Japan) were used to compute the area of the lamina 
propria in each section. The results were expressed as 
the number of each cell type per square millimetre of the 
lamina propria. 
STATISTICS 
The results for clinical data were normally distributed, and 
paired data were analysed using the two-tailed paired 
Student’s t-test. For multiple correlation, Bonferoni’s cor- 
relation was used to examine the differences in the before- 
treatment value minus the after-treatment value between 
the groups. Because the data for cell counts in the bronchial 
mucosa showed a positive skew distribution, non- 
parametric statistical tests were conducted. Paired data for 
the before- and after-treatment cell counts for immuno- 
histochemistry were analysed by Wilcoxon’s matched-pair 
signed rank test. The effects of each drug were computed by 
the differences in the before-treatment value minus the 
after-treatment value, and the group differences in the 
effects were analysed with the Kruskal-Wallis test. Data 
were expressed as median and range. A P value of ~0.05 
was regarded as statistically significant. The coefficients of 
variance for repeated counting by one observer for the 
immunostaining were 7% for EG2, 6% for AAl, 12% for 
CD3, 9% for CD4, and 7% for CDS. 
Results 
Randomization resulted in 13 patients receiving ketotifen, 
nine patients receiving DSCG, and 10 patients receiving 
BDP. Their characteristics are summarized in Table 1. 
CLINICAL DATA 
Symptom score after treatment in each group decreased 
significantly (P<O.Ol, Fig. I), and a significant difference 
after treatment was observed between the ketotifen group 
and the DSCG group or BDP group (PcO.05 each, Fig. 1). 
PEF increased significantly after treatment in the DSCG 
and BDP groups (P<O,Ol, Fig. 2; Table 2) but not in the 
ketotifen group; and significant difference after treatment 
was observed between the ketotifen group and DSCG 
group (P<O.O5). FEV,% increased after treatment in the 
DSCG and BDP groups (PcO.05, Fig. 3; Table 2), but not 
in the ketotifen group; and significant difference after 
treatment was observed between the ketotifen group and 
DSCG group (P<O.Ol) and BDP (PcO.05) group. Bron- 
chial responsiveness in terms of D,,i, in each group 
increased significantly after treatment (P<O.Ol, Fig. 4; 
Table 2); however, after treatment, there were no significant 
group differences. There were also no significant changes in 
allergen - specific IgE or total serum IgE level, before and 
after treatment (data not shown). 
IMMUNOHISTOCHEMISTRY 
At baseline, there were no significant differences in bron- 
chial mucosal cells among the three groups. EG2’ eosi- 
nophils in each group decreased significantly after 
treatment (PcO.01 each, Fig. 5) and the mean cell counts 
before and after treatment, and their ranges, are shown in 
Table 3. AAI’ mast cell counts significantly decreased after 
treatment in the DSCG (ZQO.05) and BDP (P<O.Ol) 
groups, but not in the ketotifen group (Fig. 6, Table 3). 
CD3+ T cells in each group decreased significantly after 
treatment (P<O.Ol each, Fig. 7; Table 3). CD4+ T cells in 
each group also decreased significantly (PcO.01 each, Fig. 
8; Table 3). CD8’ T cells after treatment decreased only in 
the DSCG group (P<O.Ol each, Fig. 9; Table 3). After 
treatment, only the CD8’ T cell count was significantly 
different between the ketotifen group and DSCG group, 
and between the DSCG group and BDP group (Fig. 9). 
Discussion 
No group of subjects receiving a placebo was included 
because of constraints imposed by our Ethics Committee, 
who considered a placebo group unjustified. Placebo- 
controlled studies are rare in Japan, in particular, when the 
study includes a medication of which the efficacy is being 
established. Therefore, the results of our study should be 
interpreted with some caution, and it cannot be con- 
cluded that the improvements in inflammation and asthma 
symptoms are due solely to the effects of the drugs. 
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TABLE 2. Pulmonary function data before and after treatment 
Subject 
no. 
PEF (1 min ~ ‘) 
Before After 
FEV,% pred. 
Before After 
Dmin (unit) 
Before After 
Ketotifen 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Median 
DSCG 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Median 
BDP 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Median 
480 500 89.7 90.0 2.24 3.06 
550 580 60.3 53.3 0.34 0.28 
580 600 82.9 83.4 0.26 1.0 
500 480 64.6 64.7 1.74 4.95 
480 500 82.1 85.0 0.07 0.22 
350 350 64.2 65.6 0.16 0.23 
400 510 84.4 84.4 0.15 0.17 
320 450 66.2 73.3 0.39 0.6 
450 400 65.0 63.0 0.32 0.3 
420 490 72.0 80.0 0.2 0.45 
450 500 75.8 86.6 0.99 1.73 
350 370 89.9 91.3 0.56 2.6 
450 500 58.7 71.8 0.11 0.34 
450 500 72.0 80.0 0.32 0.45** 
370 480 90.5 93.5 2.56 4.1 
480 630 60.7 67.7 0.34 0.73 
300 400 61.8 70.4 1.25 2.1 
370 450 64.4 68.3 0.32 0.56 
300 380 63.2 72.5 0.52 1.26 
320 400 57.6 64.9 0.21 0.84 
350 420 61.9 74.6 0.15 0.47 
540 600 63.5 76.8 0.33 0.73 
340 580 65.1 83.6 064 0.73 
350 450** 63.2 72.5* 0.34 0.73** 
480 500 70.2 75.5 2.03 3.07 
510 550 65.0 70.7 0.73 2.06 
330 420 70.5 76.9 1.41 1.56 
330 330 70.3 80.4 0.39 0.55 
550 570 63.0 73.0 0.63 1.41 
380 450 74.9 79.9 0.29 0.55 
250 350 59.5 65.1 0.35 0.46 
490 540 59.4 70.5 0.21 1.88 
450 520 67.0 78.0 1.2 2.4 
400 420 65.0 72.0 0.92 1.7 
425 475** 66.0 74.3* 0.63 1.63** 
*p<o.o5, **P<O.Ol: for comparison between before and after treatment. 
Before and during the study, all patients received 
&agonist inhalation when necessary. Laitinen et al. (15) 
compared budesonide, terbutaline and placebo, and found 
that in the group treated with regular terbutaline, only the 
number of lymphocytes decreased significantly. In a study 
similar to ours, Djukanovic et al. (17) demonstrated that 
BDP possesses anti-inflammatory effects on the bronchial 
mucosa and positive effects on asthma symptoms and 
bronchial responsiveness. The drugs used in treatment for 
asthma can be divided into two groups: the group of drugs 
which possess anti-inflammatory effects and can prevent 
asthma attacks (control drugs), and the other group of 
drugs which act quickly against bronchoconstriction 
(reliever drugs). According to our findings, ketotifen, 
DSCG, and BDP are shown to belong to the ‘control drugs’ 
group. 
Ketotifen significantly reduced the number of activated 
eosinophils in the bronchial mucosa of patients with 
asthma. Inhibition of eosinophil aggregation in the airway 
caused by platelet-activating factor (20) and cytokines (21) 
has been reported. The present study demonstrated the 
anti-inflammatory effect of ketotifen, in human bronchial 
mucosa in viva. In a study (22) examining the eosinophil 
content of the sputum of asthmatics with and without Intal 
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FIG. 3. Mean FEV,% pred. in each treatment group. 
Within-group comparisons were performed with Student’s 
t-test (*P<O.O5). Comparisons of each treatment effects 
(before-treatment value minus after-treatment value) were 
analysed by the Bonferroni test (*P<O.O5, **P<O.Ol). 
findings demonstrated that DSCG inhibits eosinophil infil- 
tration in the bronchial mucosa. The number of EG2’ 
eosinophils in the bronchial mucosa significantly decreased 
after BDP treatment. This is consistent with the contention 
that steroid inhalation makes eosinophil cationic protein 
(ECP) levels in BAL decrease (24) and it is consistent with 
the reports that the number of eosinophils in the bronchial 
mucosa decreases after steroid inhalation (16,17). 
Several studies have suggested that there is no difference 
in the number of mast cells between asthma patients and 
healthy subjects (4,25). Conversely, some other studies have 
indicated that the number of mast cells increases in the 
epithelium of asthmatic patients (26) and in BAL (27,28). 
Though there may be some association of mast cell num- 
bers with the fragility of the epithelium, this increase 
probably reflects the recruitment of mast cells from the 
deeper layers to the epithelium. Compared with the keto- 
tifen group, AA1 + mast cell counts in the DSCG and 
BDP groups significantly decreased. The lack of the 
effect of ketotifen on the number of mast cells would be 
attributable to the fact that mast cells were counted only in 
the submucosal area, but not in the epithelium, in order 
to exclude the effect of biopsy injury on the epithelium. 
We hypothesize that DSCG and BDP possess stronger 
anti-inflammatory effect than ketotifen. 
Asthma patients are reported to have a large number of 
T cells in the airway epithelium and in the lamina propria, 
than normal subjects (29). Robinson et al. (30) analysed 
cytokine mRNA in the cells obtained by BAL by in situ 
hybridization, and showed that various types of cells pro- 
duce IL-4 or IL-5. Recently, ketotifen was reported to be 
effective against murine recombinant IL-5-induced airway 
inflammation in guinea-pigs (31). We assumed that the 
suppressive effect of ketotifen on cytokine (IL-4 or IL-5) 
production results in a significant decrease of CD3+ and 
CD4’ T cells, but does not affect the number of CD8’ T 
cells. Further research is necessary to clarify this point. In 
the present study, all the cell counts after DSCG treatment 
r 1 
before 
Dmin 
after ** 
T 3.0 
2.5 r 
2.0 L 
.z 
3 1.5 
FIG. 4. Bronchial responsiveness to methacholine (D& 
in each treatment group. Within-group comparisons were 
performed with Student’s t-test (**P<O.Ol). 
treatment, the greatest response to Intal was observed in 
patients who had numerous eosinophils in the sputum. 
Reduction in eosinophil numbers in BAL after DSCG 
inhalation was also reported by Diaz et al. (23). Our 
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TABLE 3. Effects of treatment on cell counts in the bronchial mucosa 
EG2 AA1 CD3 CD4 CD8 
Before After Before After Before After Before After Before After 
Ketotifen 
(1020) 
22** 
(2-80) (12!:4) (i!;:) (8z:O) (4;4;;0) (557:20) (2483_;*8) (4l:l) (3ZO) 
DSCG 
(123274) (l!*;;) (124) (1;~%) 
115 89** 
(74-180) (56-128) (438:40) (;:7;) (3?87) 
36** 
(28-52) 
BDP 
(?ll3) ;:5;) (Lzl) 
l&.5** 140 90** 
(9-22) (64300) (35-148) (36?98) $i%) (2p-:o6) (1::OO) 
Values are median (range). *P<O.O5, **P<O.Ol: for comparison between before and after treatment. 
I AAl+ mast cells I n.s. P < 0.05 P< 0.01 70’ - - 
60 
01 , I I I I 1  
before after before after before after 
Ketotifen DSCG BDP 
FIG. 6. AAl’ mast cell counts in each patient, expressed 
as numbers per square millimetre of lamina propria of 
bronchial mucosa. The short horizontal bars represent 
median values. 
became significantly lower. The exact mechanisms of action 
of DSCG are not fully understood, although it is known to 
have cell- and mediator-selective suppressive effects on the 
other inflammatory cells (e.g. eosinophils, monocytes, mac- 
rophages) (32). CD3’ and CD4’ T cells decreased signifi- 
cantly after BDP inhalation, but CD8’ T cells did not. A 
possible reason is that steroids may decrease the number of 
T cells (33), in particular, that of CD4+ cells (34), in 
peripheral blood. Bentley et al. (35) reported that the 
number of cells which express IL-4 and IL-5 mRNAs in the 
bronchial mucosa of asthmatic patients, decreased signifi- 
cantly after steroid therapy. The reduction in the number of 
T cells after BDP inhalation in our study may be a result 
of the inhibited cytokine production caused by BDP. 
Recently, it has been suggested that each group in such a 
biopsy study as ours needs at least 15 patients in order to 
provide sufficient statistical power to detect most of the 
changes in the biopsies of the airways (36). In the present 
study, each group had a limited number of patients, 
i.e. between nine and 13 subjects, and no significant changes 
were observed in the counts of eosinophils, mast cells, 
and CD4’ T cells in spite of the use of BDP ,which 
possesses the most potent anti-inflammatory effect. If an 
! CD3+ T lymphocytes PC 0.01 P< 0.01 P< 0.01 300 - - i- 
250 - 
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FIG. 7. CD3+ T-lymphocyte counts in each patient, 
expressed as numbers per square millimetre of lamina 
propria of bronchial mucosa. The short horizontal bars 
represent median values. 
examination with a larger number of subjects is conducted, 
it could demonstrate additional effects of the drugs on 
inflammatory cells. 
Our post-treatment clinical data showed significant 
improvements in the symptom score and bronchial respon- 
siveness in the three groups. The change in PEF was the 
largest in the DSCG group. Both the DSCG and BDP 
groups showed larger changes in FEV,% than the ketotifen 
group. In long-term clinical trials, the efficacy and tolerance 
of ketotifen have been reported (37,38), and ketotifen has 
been reported to improve pulmonary function (12,38,39), 
though contradictory data (11,19) have also been pub- 
lished. DSCG reduces severity of asthma symptoms, fre- 
quency of exacerbations (40,41), and airway responsiveness, 
in patients with asthma (42). Other studies also demon- 
strated that ketotifen, DSCG and BDP improve lung 
function, decrease airway hyperresponsiveness, reduce the 
severity of symptoms, decrease frequency of exacerbations, 
and improve quality of life (43-45). 
In the present study, ketotifen, DSCG, and BDP all 
exerted anti-inflammatory activity in the bronchial 
mucosa of asthmatic patients, and the DSCG and 
BDP groups demonstrated superior clinical responses 
CD4+ T lymphocytes 
P< 0.01 P< 0.01 P-L 0.01 
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FIG. 8. CD4+ T-lymphocytes counts in each patient, 
expressed as numbers per square millimetre of lamina 
propria of bronchial mucosa. The short horizontal bars 
represent median values. 
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FIG. 9. CD8’ T-lymphocytes counts in each patient, 
expressed as numbers per square millimetre of lamina 
propria of bronchial mucosa. The short horizontal bars 
represent median values. The differences (before-treatment 
value minus after-treatment value) in cell counts for each 
treatment group were compared by using the Kruskal- 
Wallis test. 
as compared to the ketotifen group. We conclude that 
DSCG and BDP could result in a better improvement than 
ketotifen. 
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